Antioxidant strategies in the treatment of stroke

Isabelle Margaill1, Michel Plotkine, Dominique Lerouet

  • 1Faculté des Sciences Pharmaceutiques et Biologiques, Laboratoire de Pharmacologie (UPRES EA 2510), Université René Descartes, 4 avenue de l'Observatoire, 75006 Paris, France. isabelle.margaill@univ-paris5.fr

Insights

Antioxidants show promise for treating ischemic stroke by combating oxidative stress. Strategies include inhibiting free radical production, scavenging radicals, and enhancing their degradation, with ongoing clinical trials for stroke patients.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Pharmacology

Background:

  • Excessive free radical production causes cell injury in diseases like cerebral ischemia.
  • Oxidative stress is a significant factor in the pathophysiology of focal cerebral ischemia.

Purpose of the Study:

  • To review studies on oxidative stress and antioxidant strategies in focal cerebral ischemia.
  • To evaluate the efficiency of various antioxidant approaches in preclinical models and clinical trials for stroke.

Main Methods:

  • Examination of studies using genetically modified mice to investigate oxidative stress.
  • Categorization of antioxidant strategies into inhibition of production, scavenging, and enhanced degradation.
  • Review of clinical trials assessing antioxidant efficacy in stroke patients.

Main Results:

  • Multiple antioxidant strategies have been explored in preclinical models of focal cerebral ischemia.
  • Clinical trials are actively investigating the therapeutic potential of antioxidants for stroke treatment.
  • Evidence suggests antioxidants are a promising therapeutic avenue for ischemic stroke.

Conclusions:

  • Antioxidant therapies represent a highly promising approach for the treatment of ischemic stroke.
  • Further research and clinical validation are crucial to fully realize the potential of antioxidants in stroke management.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
Ischemic Stroke ll: Pathophysiology01:15

Ischemic Stroke ll: Pathophysiology

An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...